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AbstrACt
Introduction Short-term psychodynamic psychotherapy 
(STPP) is an empirically supported treatment that is often 
used to treat depression. However, it is largely unclear 
if certain subgroups of depressed patients can benefit 
specifically from this treatment method. We describe 
the protocol for a systematic review and meta-analysis 
of individual participant data (IPD) aimed at identifying 
predictors and moderators of STPP for depression efficacy.
Method and analysis We will conduct a systematic 
literature search in multiple bibliographic databases 
(PubMed, PsycINFO,  Embase. com, Web of Science and 
Cochrane’s Central Register of Controlled Trials), ‘grey 
literature’ databases (GLIN and UMI ProQuest) and a 
prospective trial register (http://www. controlled- trials. 
com). We will include studies reporting (a) outcomes on 
standardised measures of (b) depressed (c) adult patients 
(d) receiving STPP. We will next invite the authors of these 
studies to share the participant-level data of their trials 
and combine these data to conduct IPD meta-analyses. 
The primary outcome for this study is post-treatment 
efficacy as assessed by a continuous depression 
measure. Potential predictors and moderators include 
all sociodemographic variables, clinical variables and 
psychological patient characteristics that are measured 
before the start of treatment and are assessed consistently 
across studies. One-stage IPD meta-analyses will be 
conducted using mixed-effects models.
Ethics and dissemination Institutional review board 
approval is not required for this study. We intend to submit 
reports of the outcomes of this study for publication 
to international peer-reviewed journals in the fields of 
psychiatry or clinical psychology. We also intend to present 
the outcomes at international scientific conferences aimed 
at psychotherapy researchers and clinicians. The findings 
of this study can have important clinical implications, 
as they can inform expectations of STPP efficacy for 
individual patients, and help to make an informed choice 
concerning the best treatment option for a given patient.
PrOsPErO registration number CRD42017056029.
IntrOduCtIOn  
Depression is a highly prevalent and disabling 
disorder associated with major personal 
and societal costs.1 Affecting more than 
300 million people worldwide, depression 
is ranked as the single largest contributor 
to global disability by the WHO.2 Given the 
tremendous burden of disease, there is a great 
need for effective and efficient treatments for 
depression. Antidepressant medications and 
different psychological therapies constitute 
strengths and limitations of this study
 ► This is the first study that systematically assesses 
patient characteristics associated with short-
term psychodynamic psychotherapy (STPP) for 
depression efficacy.
 ► Individual participant data (IPD) meta-analysis allows 
for the examination of predictors and moderators 
by maximising statistical power while protecting 
against ecological bias that presents problems when 
using conventional meta-analysis techniques.
 ► The findings of this study can have important clinical 
implications, as they can inform expectations of 
STPP efficacy for individual patients, and help to 
make an informed choice concerning the best 
treatment option for a given patient.
 ► IPD meta-analyses rely on variables previously 
assessed in individual studies and available across 
multiple trials. Thus, it is possible that not all 
variables of interest can be examined as potential 
predictors or moderators.  on 20 F
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the predominant treatments for depressive disorders.3 
Concerning psychological treatments, there is a clinical 
tradition of short-term psychodynamic psychotherapies 
(STPPs) being used to treat depression. STPP is an empir-
ically supported treatment for depression.4 However, it 
is unlikely that any treatment will work equally well for 
all depressed patients,5 and it remains largely unclear if 
certain subgroups of patients can benefit specifically from 
STPP.
Two types of information are relevant to this question: 
predictors and moderators. Predictors (or prognostic 
factors) predict outcome to a given treatment and can 
be used to determine which patients are more likely to 
respond to STPP relative to other patients. For instance, 
if age were found to be a positive predictor of STPP effi-
cacy, this might indicate that older patients would be 
more likely to benefit from STPP than younger patients. 
Predictors can inform expectations of STPP efficacy, but 
are of little use in deciding which treatment to select. 
On the other hand, moderators (or prescriptive factors) 
can detect different patterns of outcomes between 
different treatments for different types of patients and 
provide a basis for choosing the best treatment for a 
given patient.6 For instance, if age were found to be a 
moderator of STPP efficacy versus antidepressant medi-
cation, this might indicate that older patients might 
benefit more from STPP than from medication, while 
younger patients might benefit more from medication 
than from STPP.
Some preliminary empirical findings concerning 
predictors and moderators of STPP efficacy for depres-
sion do exist. With regard to predictors, meta-regres-
sion analyses alongside a ‘conventional’ meta-analysis 
(based on results extracted from publications4) showed 
that mean pretreatment depression scores were posi-
tively associated with pretreatment to post-treatment 
depression effect size, although this effect might not be 
specific to STPP.7 With regard to moderators, Driessen et 
al 8 found STPP to be more efficacious than CBT among 
depressed patients who showed low baseline comorbid 
anxiety levels. Furthermore, Barber et al 9 reported that 
STPP was more efficacious than medication or placebo 
for ethnic minority males. However, a systematic assess-
ment of which patient characteristics are associated with 
STPP efficacy is currently lacking.
The main reason why predictors and moderators of 
STPP for depression have not yet been examined thor-
oughly is lack of statistical power in individual clinical 
trials due to relatively small sample sizes. Prediction 
and moderation analyses can also be conducted along-
side conventional meta-analyses. However, since these 
analyses are usually based on study-level characteristics, 
they are prone to ecological bias, such that the associa-
tion between the study-level characteristics may not be 
representative of the true relationships in the data at the 
individual level.10 Thus, current research methods (clin-
ical trials and conventional meta-analyses) have been 
insufficient to answer the question as to whether certain 
subgroups of patients can benefit specifically from STPP 
for depression.
Individual participant data (IPD) meta-analysis is a 
relatively new technique to examine treatment effects 
by combining participant-level data of multiple trials. 
IPD meta-analysis uses the same basic approach as any 
other well-conducted systematic review and meta-analysis. 
However, it involves collection of the original data from as 
many of the relevant trials worldwide as can be accessed. 
IPD meta-analysis has several advantages over conven-
tional meta-analysis, including increased statistical power 
to examine predictors and moderators of treatment effi-
cacy.11 Furthermore, because predictors and moderators 
are studied at patient level, ecological bias can be circum-
vented. For these reasons, IPD meta-analysis is currently 
considered the ‘gold standard’ in evidence synthesis.12
We describe the study protocol for a systematic review 
and IPD meta-analysis concerning predictors and moder-
ators of STPP for depression efficacy. The aim of this 
project is to examine which depressed patients benefit 
specifically from STPP in terms of depressive symptom 
reduction when compared with other patients (predic-
tors), and which patients benefit specifically from STPP 
when compared with no-treatment conditions, other 
psychotherapies and antidepressant medication (moder-
ators). The goal of this study is to collect the partici-
pant-level data of trials examining the efficacy of STPP 
for depression identified by a systematic literature search, 




This study is a systematic review and meta-analysis of 
IPD that is registered in the PROSPERO International 
prospective register of systematic reviews (registration 
number: CRD42017056029). Important protocol amend-
ments will be documented in this register too. The 
project started on 1 December 2016 and is expected to be 
completed by 31 July 2019.
search strategy
We will use an extensive search strategy including six 
different search methods in order to retrieve as many rele-
vant studies as possible. These searches have already been 
performed in 2007 and 2014 for two previous conven-
tional meta-analyses concerning the efficacy of STPP for 
depression4 13 and will be updated in 2017.
First, we will systematically search the bibliographic 
databases PubMed, PsycINFO (via EBSCO),  Embase. com, 
Web of Science (via Elsevier) and Cochrane’s Central 
Register of Controlled Trials (via Wiley). Search terms 
will include a wide range of synonyms, both in index 
terms and free-text words, for (1) psychodynamic psycho-
therapy (eg, psychotherapy, psychoanalytic), (2) therapy 
(eg, psychotherapy), (3) psychodynamic (eg, dynamic*) 
and (4) depression (eg, depressive disorder). These four 
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sets of search terms will be combined as follows: (#1 OR 
(#2 AND #3)) AND #4. The exact terms for the search in 
PubMed are presented in table 1. Complete search terms 
for all electronic databases are available on request from 
the corresponding author. No language or date restric-
tions will be applied in the searches.
Second, in order to identify relevant studies from the 
so-called ‘grey literature’, we will search GLIN, a Dutch 
electronic database for grey literature, and UMI database 
ProQuest for digital dissertations. Third, a prospective 
trial register will be searched for unpublished ongoing 
research (http://www. controlled- trials. com). The grey 
literature and prospective trial register searches will be 
conducted using the search strategy described above. 
Fourth, we will search an Internet database of controlled 
and comparative outcome studies on psychological treat-
ments of depression (http://www. psychotherapyrcts. 
org14) for studies examining STPP. Fifth, reviews and 
meta-analyses concerning the efficacy of psychodynamic 
treatments for depression or for psychiatric disorders in 
general retrieved from the first search method will be 
screened for relevant references not located by means of 
the other search methods. Sixth, we will contact an email 
list of researchers in the field of psychodynamic therapy 
to ask for ongoing or unpublished studies.
selection of studies
We will include studies if they report (a) outcomes on stan-
dardised measures of (b) depressed (c) adult patients (d) 
receiving STPP. Participants are considered depressed if 
they meet specified criteria for major depressive disorder 
or another unipolar mood disorder as assessed by means 
of a semistructured interview or clinicians’ assessment, or 
if they present an elevated score above the ‘no depres-
sion’ cut-off on a standardised measure of depression. 
Participants need to be at least 18 years old, and studies 
concerning older adults (mean age>55) will be included 
as well. We will include studies in which STPP (a) is based 
on psychoanalytic theories and practices, (b) is time-lim-
ited from the onset (ie, not a therapy that is brief only in 
retrospect) and (c) applies verbal techniques (eg, thera-
pies applying art as expression form are not considered 
STPP). Studies need to include at least 10 subjects. Case 
studies will therefore be excluded. We will also include 
naturalistic studies with a heterogeneous study sample, if 
these studies include more than 10 participants diagnosed 
as depressed, as these subgroups also meet the inclusion 
criteria specified previously. For these studies, the authors 
will be contacted with a request for subgroup data.
The screening process will consist of three phases. 
At first, the selection criteria will be applied to the cita-
tions generated from the searches independently by two 
raters. Disagreements will be discussed and resolved by 
consensus. Unless they can be definitely excluded, titles 
identified as potentially relevant will be requested in full 
text. During the second screening phase, two indepen-
dent raters will apply the selection criteria to the full-text 
papers. Disagreements will be discussed and resolved 
by consensus. During the third phase, two expert STPP 
raters will confirm that the included papers meet criteria 
for STPP. Again, disagreements will be discussed and 
resolved by consensus. When disagreements cannot be 
resolved in this way, a third rater will be consulted.
Table 1 PubMed search strategy
Search PubMed query 19-06-2017 Items found
#1 Search “Psychoanalytic Therapy”[Mesh] OR “Psychotherapy, Psychodynamic”[Mesh] OR 
psychodynamic*[tiab] Sort by: Relevance
20 177
#2 Search (“Psychotherapy”[Mesh:noexp] OR “Animal Assisted Therapy”[Mesh] OR “Art 
Therapy’(Mesh) OR “Bibliotherapy”[Mesh] OR “Psychotherapy, Group”[Mesh] OR “Psychotherapy, 
Brief”[Mesh] OR “Psychotherapy, Multiple”[Mesh] OR “Counselling”[Mesh:NoExp] OR “Directive 
Counselling”[Mesh:NoExp] OR ((psychotherap*[tiab] OR therap*[tiab] OR counselling[tiab]) NOT 
medline[sb]))
380 901
#3 Search dynamic*[tiab] OR STPP[tiab] OR BDT(tiab] OR DIT[tiab] OR insight*[tiab] OR interpretive[tiab] 
OR interpretative[tiab] OR analytic*[tiab] OR psychoanalytic*[tiab]
1073 217
#4 Search #2 AND #3 21 435
#5 Search #1 OR #4 39 841
#6 Search Depressive disorder[Mesh] OR depression[Mesh] OR ((depress*[tiab] OR melancholia*[tiab] OR 
dysphoria*[tiab] OR dysthymi*[tiab] OR “seasonal affective disorder”[tiab]) NOT medline[sb])
223 737
#7 Search #5 AND #6 2350
#8 Search #7 NOT (“addresses”[Publication Type] OR “biography”[Publication Type] OR 
“comment”[Publication Type] OR “directory”[Publication Type] OR “editorial”[Publication Type] OR 
“festschrift”[Publication Type] OR “interview”[Publication Type] OR “lectures”[Publication Type] 
OR “legal cases”[Publication Type) OR “legislation”[Publication Type) OR “letter”[Publication Type) 
OR “news”[Publication Type) OR ‘newspaper article”[Publication Type) OR ‘patient education 
handout”[Publication Type] OR “popular works”[Publication Type] OR “consensus development 
conference’[Publication Type] OR “consensus development conference, nih”[Publication Type])
2285
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data collection
Authors of the included studies will be contacted and 
invited to contribute the participant-level data of their 
studies. Researchers who share their data will be offered 
coauthorship for all publications that are based on their 
study’s data (group-authorship), given that they meet 
standard criteria for authorship of scientific publica-
tions according to internationally accepted criteria (www. 
icmje. org). In addition, the collected data will be made 
available to investigators who contribute data to examine 
other research questions in the combined dataset. This 
strategy has been used in previous IPD meta-analyses 
concerning depression treatments15 16 and has been 
successful in convincing researchers to share their data.
Contact details of all first authors will be collected 
from the relevant publications, or if not reported there, 
through Internet searches or personal contacts with 
other researchers. First authors will be contacted by email 
with a letter of invitation outlining the project’s goals and 
asking if they would be willing to collaborate by sharing 
the participant-level data of their trial. If an author does 
not respond after 3 weeks, a second and third email will 
be sent. In case of non-response to email, a letter will be 
sent (again with three attempts). If still no response is 
received, we will try to contact the author by telephone. If 
all these attempts fail, the last, second, third, fourth, etc. 
author of the study (in this order) will be contacted in the 
same way. If none of the authors respond to these efforts, 
other ways will be sought to contact one of the authors 
(eg, via colleagues or anyone who might know them). 
Study data will be considered unavailable only if all these 
attempts fail, or in the event that an author indicates 
that the participant-level data have not been retained or 
declines sharing these data.
If the author is willing and able to share the IPD of 
his/her trial, both parties will sign a data-sharing agree-
ment. The author will then transfer the participant-level 
dataset, including all potential predictors and modera-
tors assessed before the start of treatment, as well as all 
outcome variables assessed during and after treatment, 
both in the STPP condition as well as in any comparison 
condition included in the study. The author will anony-
mise the data, so that the dataset is transferred without 
containing personal information that can lead back to 
individuals. Data can be submitted to the project in any 
format, and will then be converted to Stata.
data integrity check
After the dataset has been transferred, the file will be 
checked to examine whether the data received match 
the data reported in the publication. For all treatment 
conditions included in the study, sample size, number of 
females, mean age, observed mean pretreatment depres-
sion scores, observed mean post-treatment score for the 
primary depression outcome and the number of missing 
cases for the latter will be calculated from the dataset 
received and checked against the published article for this 
purpose. Discrepancies will be resolved with the authors. 
In addition, the data will be checked for invalid, out-of-
range, or inconsistent items. Furthermore, we will check 
the integrity of the randomisation for randomised studies 
by inspecting the balance of the potential predictor/
moderator variables across treatment arms.
For each study, we will list all predictor/moderator 
variables that were assessed, as well as all outcome vari-
ables, intermediate and follow-up assessments. We will 
also extract multiple STPP characteristics (eg, number of 
sessions, treatment format, STPP mode) and study design 
characteristics (eg, therapist training, treatment integrity 
check, use of a treatment manual; for a complete over-
view see4). Finally, we will extract study validity criteria 
according to the Cochrane risk of bias assessment tool.17
After checking the data, the datasets will be stan-
dardised. For this purpose, a copy of each trial’s raw data 
file will be recoded into a data file that matches the IPD 
meta-analysis database in terms of variables. Next, the 
individual study data files will be concatenated in one 
database structured by study and individual participant 
ID. After all data files have been recoded and entered, the 
data for each study will be checked with the original data 
file received for accuracy. A codebook document will be 
made that includes the coding of the individual studies 
as well as the coding of the combined study database. 
Coding for the database will be finalised when all data 
have been received from the study authors.
Measures
The primary outcome for this study is treatment efficacy 
as assessed by a continuous depression outcome measure 
at post-treatment. We have chosen depressive symptom 
status as the main outcome for this study as we consider 
this to be the primary target of STPP for depression. We 
chose continuous symptom level as the primary outcome, 
because we expect that the increased variance relative 
to dichotomous outcomes might facilitate the search for 
predictors and moderators. We have chosen post-treat-
ment assessment as the primary end point as it is difficult 
to control additional treatment in the follow-up period in 
psychotherapy efficacy studies (eg, reference 18).
For each trial, we will identify the primary continuous 
depression outcome as defined by the study authors. All 
instruments explicitly measuring depression qualify in 
this regard. Different depression measures have prob-
ably been used and, therefore, we will standardise the 
depression outcomes by converting the depression scores 
into z-scores. Sensitivity analyses will be conducted using 
unstandardised scores for each depression measure that 
is assessed in the majority of studies included in the 
meta-analysis (eg, Hamilton Depression Rating Scale,19 
Beck Depression Inventory20).
The secondary outcomes for this study are dichotomous 
depression outcomes for (1) response (a 50% reduction 
in symptoms from pretreatment to post-treatment) and 
(2) remission (maximum absolute post-treatment scores 
reflecting normalisation). In addition, outcome measures 
other than depression will be collected (eg, anxiety 
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symptoms, quality of life, interpersonal functioning). 
These can be considered tertiary outcomes.
Potential predictors and moderators include sociode-
mographic variables (eg, gender, age, education level, 
marital status, employment status, ethnicity), clinical 
variables (eg, number of previous depressive episodes, 
previous exposure to treatment, comorbid Axis I and II 
psychopathology, global assessment of functioning) and 
psychological patient characteristics (eg, personality 
organisation, attachment, interpersonal styles, childhood 
maltreatment, alexithymia). These are likely assessed 
differently in individual studies and will be standardised 
as well, for instance by converting scores into z-scores for 
continuous variables or by recoding variables into similar 
categories for categorical variables. In the latter case, we 
will consult study authors to confirm correctness of the 
recoding.
Missing data
All datasets received that contain IPD, at least one rele-
vant outcome measure and at least one predictor/moder-
ator variable will be considered for quantitative synthesis. 
We will examine the possibility of complete-case anal-
yses by evaluating the extent of missing data as well as 
the possible reasons for missing data, and by comparing 
patients with complete data to patients with missing data. 
We will also assess whether the missing data can be consid-
ered missing at random.21 If complete-case analysis is not 
justifiable and data can be considered missing at random, 
we will impute missing data using multiple imputation, 
which is currently considered to be the most sophisti-
cated method for handling missing data.22
We will generate one imputed dataset for each percent 
of missing data (eg, when 30% of the data are missing, we 
will create 30 imputed datasets). We will impute missing 
data by means of hierarchical imputation with fully condi-
tional specification for the generalised linear model 
(FCS-GLM),23 which allows for preserving the heteroge-
neity across studies, non-normal distributions of variables 
and imputing systematically missing variables. FCS-GLM 
has shown to be a reliable procedure with advantageous 
properties for IPD meta-analyses with limited numbers of 
studies or studies with small sample sizes.24 FCS-GLM will 
be conducted in R. To ensure congeniality, imputation 
will be based on all variables that will be included in the 
meta-analysis model including their interactions as well 
as any variables that were identified to be predictive of 
missing values.24 If multiple imputation is pursued, we will 
conduct sensitivity analyses restricted to complete cases 
and compare the results. We will not pursue efforts to 
combine IPD with aggregate data from studies for which 
no IPD is available,25 since the requisite treatment-co-
variate interactions are seldom reported in publications.
data analysis
We will conduct IPD meta-analyses according to the 
one-stage approach, because that accounts for the 
correlation among model parameters when modelling 
interactions, offers the highest degree of flexibility for 
making the necessary assumptions when detecting treat-
ment-covariate interactions,26 and provides a more exact 
likelihood in the case of small studies.27 We will conduct 
IPD meta-analyses using mixed models with restricted 
maximum likelihood to estimate between-study heteroge-
neity, which is recommended when there are few studies 
in the meta-analysis or studies have small sample sizes.28 
Analyses will be conducted in Stata ‘mixed’. We will apply 
the Kenward-Roger denominator-degrees-of-freedom 
adjustment for CIs,29 because it more adequately 
accounts for uncertainty than the standard Dersimoni-
an-Laird estimator when the number of studies is small 
or when heterogeneity is present.30 To account for clus-
tering of patients within studies and to preserve rando-
misation, we will include a random intercept for study 
and a random slope for baseline depression. We assume 
that these random effects will be normally distributed and 
this assumption will be assessed. We will assess heteroge-
neity by examining the SD of the predictor or moderator 
parameter estimates.
Separate analyses will be conducted for the identifica-
tion of predictors and the identification of moderators 
of STPP efficacy. With regard to predictors, IPD from 
STPP conditions across all studies will be combined, 
regardless of study type (randomised controlled study, 
non-random comparative study, naturalistic study). For 
each of the potential predictors, a model will be esti-
mated with baseline depression and the predictor’s main 
effect. A random slope will be added to the predictor to 
examine if this results in a model improvement. If so, this 
predictor variable will be included with a random slope in 
subsequent analyses. Next, all predictors will be modelled 
simultaneously. Backward selection based on P value will 
be conducted until a final prediction model is obtained 
consisting of statistical significant predictors only. This 
prediction model will be validated in a held-out sample 
of the data.
With regard to moderators, analyses will be conducted 
separately for each comparison (eg, STPP vs control 
conditions, STPP vs other psychotherapy and STPP vs 
antidepressant medication). These analyses will only 
include IPD from randomised studies. For each of the 
potential moderators, a model will be estimated with 
baseline depression as well as the moderator’s main effect 
and interaction with treatment. Next, to examine ecolog-
ical bias, within-study and across-study interaction effects 
will be separated.25 If within-study and across-study inter-
actions differ, ecological bias may be at play, and only the 
within-trial interaction will be interpreted in subsequent 
analyses. Finally, all significant treatment-covariate inter-
actions, their main effects and higher order interactions 
will be modelled simultaneously. The resulting prediction 
model will be validated in a held-out sample of the data.
A number of sensitivity analyses will be conducted to 
examine the robustness of the findings. To examine the 
impact of study quality, we will conduct sensitivity anal-
yses including only studies that score high on all quality 
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criteria. In addition, we will conduct analyses in which we 
add the risk of bias items as covariates to the mixed-effects 
models, centred at a value indicating freedom of bias.31 
We will also conduct sensitivity analyses to control for 
the effects of additional non-study treatment during the 
trial and in the follow-up period by adding collected data 
in this regard as covariates to the mixed-effects models. 
Finally, we will examine the impact of STPP character-
istics (eg, STPP type, delivery mode) and study design 
characteristics (eg, therapist training, use of a treatment 
manual) by adding these variables to the mixed-effects 
models too.
Furthermore, to examine possible data availability 
bias, t-tests and Χ2 analyses will be conducted comparing 
the included studies with studies for which no partici-
pant-level data was obtained with regard to the extracted 
study characteristics. Conventional meta-analysis tech-
niques will be used to examine differences in effect 
sizes between studies that contributed data and studies 
that did not. We will assess potential publication bias by 
assessing asymmetry in contour-enhanced funnel plots 
for meta-analyses including 10 or more trials, as is recom-
mended by Sterne et al.32 The confidence in the cumu-
lative body of evidence will be assessed according to the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system.33
In addition, we will conduct explorative analyses using 
tree-based statistical learning. More specifically, we 
will use the generalised linear mixed-effects regression 
trees algorithm (glmertree34) in R to detect predictors 
and moderators of continuous and binary treatment 
outcomes. These analyses offer several advantages over 
more traditional mixed-effects modelling approaches, as 
they allow for the detection of non-linear and higher level 
interactions, allow for specifying a large number of poten-
tial predictor and moderator variables and involve less 
stringent assumptions about the distribution of the data. 
Furthermore, the result of applying glmertree consists 
of a decision tree that graphically depicts the effects of 
the relevant predictor and moderator variables. Such 
a tree can easily be interpreted, and applied in clinical 
decision-making. However, it should be noted that such 
tree-based analyses are exploratory in nature. We will 
assess the expected predictive accuracy on new data using 
k-cross validation35 and the stability of the resulting deci-
sion trees using subsampling methods.36 The glmertree 
analyses will be performed using observed, non-imputed 
data only, as it is currently unclear how to best specify the 
model for generating imputed data in tree-based analyses 
for clustered data.
EthICs And dIssEMInAtIOn
Institutional review board (IRB) approval was not required 
for this project. IRB approval may be required for the 
investigators to share their primary data depending on 
their institution’s policies. It is the responsibility of the 
investigators to obtain IRB approval if their institution’s 
policies require them to do so. By signing the data-sharing 
agreement, the authors who share their data declare that 
those data were collected and transferred to our research 
group according to all applicable local and international 
laws and regulations, including but not limited to local 
IRB approval.
We intend to submit reports of the outcomes of this 
study for publication to international peer-reviewed jour-
nals in the fields of psychiatry or clinical psychology. We 
also intend to present the findings of this study at inter-
national scientific conferences aimed at psychotherapy 
researchers and clinicians.
dIsCussIOn
We described the study protocol of a systematic review and 
meta-analysis of IPD to examine predictors and modera-
tors of STPP efficacy for depression. The goal of this study 
is to collect the participant-level data of studies exam-
ining the efficacy of STPP for depression identified by a 
thorough literature search, and to combine these data-
sets in order to conduct IPD meta-analyses. The proposed 
study design allows for the examination of predictors 
and moderators of STPP efficacy with increased statis-
tical power and can thus help to show which subsets of 
depressed patients specifically benefit from therapies 
based on psychoanalytic principles.
Clinical and scientific relevance
In contrast to how commonly STPPs are used in clinical 
practice, they are under-represented in current treatment 
guidelines for depressive disorders. Further high-quality 
research that extends and disseminates knowledge about 
the effectiveness of STPP is therefore called for. Research 
showing whether subsets of depressed patients can specif-
ically benefit from this therapy modality, especially when 
compared with other treatments, is particularly needed. 
Knowledge of such moderators can have important impli-
cations for clinical practice, as it can be used to guide 
treatment selection and increase the efficiency of treat-
ments for depression by helping patients and clinicians to 
make an informed choice concerning the best treatment 
option for a given patient.
Little is known about patient characteristics associated 
with STPP efficacy, because clinical trials often have rela-
tively small sample sizes and limited statistical power to 
examine predictors and moderators of change. More-
over, prediction and moderation analyses in conventional 
meta-analyses are often based on study-level aggregates 
and are, therefore, prone to ecological bias. By means 
of IPD meta-analyses, these critical limitations can be 
overcome. IPD meta-analyses have been utilised more 
frequently in the medical field, but are newer in the field 
of psychiatry and clinical psychology.37 Although IPD 
meta-analyses have now been used to examine single 
moderators of CBT and pharmacotherapy efficacy for 
depression,20 21 to date no IPD meta-analysis has been 
conducted concerning STPP.
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strengths and limitations
IPD meta-analysis has several advantages over conven-
tional meta-analysis, including increased statistical power 
to examine predictors and moderators.11 In addition, by 
collecting the primary data, access to predictor or moder-
ator variables that might not have been reported in the 
published articles is gained; increasing the chance that 
aggregation of these variables across studies is possible. 
Other advantages of IPD meta-analysis over conventional 
meta-analysis include the possibility to (1) account for 
missing data at the individual participant level, so that, for 
instance, intention-to-treat analyses can be conducted, 
even though the original study reported completers-
only analyses, (2) use the same statistical methods for 
imputing missing data and for conducting statistical anal-
yses, thereby facilitating standardisation across studies, 
(3) standardise outcomes across studies, for instance 
by using equal cut-off points on a depression outcome 
measure when the primary studies used different cut-offs 
and (4) verify the results presented in the original studies, 
also by means of more sophisticated statistical techniques 
that were not available at time of publication in the case 
of older studies.38
IPD meta-analyses involve collection of original data 
from all the relevant trials worldwide that can be accessed. 
These data need to be prepared and checked before 
being included in the meta-analysis, and complex deci-
sions on the data sometimes need to be made in order to 
ensure the accuracy of the outcomes. Therefore, it takes 
more time and resources to conduct an IPD meta-anal-
ysis than to conduct a conventional meta-analysis based 
solely on results extracted from published trial reports.38 
However, the IPD approach can improve the quality of 
both the data and the analyses, and so the reliability of 
the results. Therefore, it is considered the ‘gold standard’ 
of meta-analysis.12
IPD meta-analyses also have a number of limitations. 
First, although IPD meta-analyses are generally consid-
ered the most reliable approach to evidence synthesis,12 
this does not mean that they are bias-free and selection 
bias, publication bias and data availability bias need to 
be considered.39 We try to overcome this limitation by 
performing a systematic literature search that also aims 
to identify grey literature and unpublished work, and 
by testing for differences between studies for which IPD 
was and was not obtained. Second, IPD meta-analyses 
rely on variables previously assessed in individual studies 
and available across multiple trials. For this reason, it is 
possible that not all variables of interest can be exam-
ined as potential predictors or moderators. Third, and 
related, it is necessary to standardise predictor/moder-
ator variables for the analyses, but doing so might involve 
recoding and possibly omitting important information 
for some variables. Fourth, although combining multiple 
trials reduces the possibility that predictors/moderators 
identified are chance findings in single-study samples, 
generalisability of the findings might still be limited to 
patients who volunteer to participate in scientific outcome 
research. Fifth, the predictors and moderators identified 
in this study can either apply specifically to STPP or can 
be more general factors associated with depression treat-
ment efficacy. We intend to address this distinction in this 
study’s outcome reports in the context of the predictors/
moderators identified.
Conclusion
We described the study protocol for a systematic review 
and meta-analysis of IPD aimed at examining if certain 
subgroups of depressed patients can benefit specifically 
from STPP. We will collect the participant-level data 
of studies examining the efficacy of STPP for depres-
sion identified by a thorough literature search. We will 
combine these datasets and conduct IPD meta-analyses 
to identify predictors and moderators of STPP efficacy. 
Knowledge of such predictors and moderators can have 
important implications for clinical practice, as they can, 
respectively, inform expectations of treatment efficacy for 
individual patients, and help patients and clinicians to 
make an informed choice concerning the best treatment 
option for a given patient.
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